Clinical Trial SuccessCYTK's lead asset aficamten demonstrated superiority to beta blocker metoprolol in the pivotal Ph.3 MAPLE-HCM trial, meeting its primary endpoint of improved peak oxygen uptake in patients with obstructive hypertrophic cardiomyopathy.
Product DifferentiationAficamten is believed to provide a differentiated profile relative to Camzyos, with advantages in efficacy, safety, and pharmacology.
Regulatory ReviewWith aficamten under regulatory review in the US, EU, and China, these comparative efficacy data could help it strengthen its commercial positioning.